See up to 3 months of RGEN. The 7-day demo opens the 1M and 3M ranges and puts RGEN on your watchlist.
Start 7-day demoLatest RGEN insider trades
Olivier Loeillot - OfficerOpen-market sale$238K- Olivier Loeillot
About REPLIGEN CORP (RGEN)
REPLIGEN CORP is an SEC registrant, filing under CIK 0000730272, classified as biological products (no diagnostic substances). It is grouped with Health Care companies on this site.
RGEN Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 7 | 32,368 | $5.95M |
| Grant or award | 3 | 3,841 | |
| Option exercise | 10 | 56,000 | |
RGEN insider transactions (Form 4)
5956 Form 4 filings on record, the earliest from Nov 20, 2024, newest first. Filing history page 2 of 2.
| Traded | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Anthony Hunt | Tax withholding / forfeiture | Common Stock | 9,897 footnote F1 | $124.97 | $1.24M | |
| ||||||
| Jason K. Garland - Officer | Tax withholding / forfeiture | Common Stock | 327 footnote F1 | $128.73 | $42K | |
| Jason K. Garland - Officer | Tax withholding / forfeiture | Common Stock | 715 footnote F1 | $124.97 | $89K | |
| ||||||
| Ralf Kuriyel - Officer | Tax withholding / forfeiture | Common Stock | 444 footnote F1 | $128.73 | $57K | |
| Ralf Kuriyel - Officer | Tax withholding / forfeiture | Common Stock | 923 footnote F1 | $124.97 | $115K | |
| ||||||
 Brian Robb Douglass - Officer | Tax withholding / forfeiture | Common Stock | 221 footnote F1 | $124.97 | $28K | |
| ||||||
| Brian Robb Douglass - Officer | Grant or award | Common Stock | 2,288 footnote F1 | $0.00 | - | |
| Brian Robb Douglass - Officer | Grant or award | Stock Option (Right to Buy) | 2,143 | $0.00 | - | |
| ||||||
| Karen A. Dawes | Open-market sale | Common Stock | 275 | $161.00 | $44K | |
| Glenn P. Muir | Option exercise | Common Stock | 3,366 | $26.12 | $88K | |
| Glenn P. Muir | Option exercise | Stock Option (Right to Buy) | 3,366 | $0.00 | - | |
| Anthony Hunt | Other | Common Stock | 2,000 | - footnote F1 | - | |
| ||||||
| Olivier Loeillot - Officer | Open-market sale | Common Stock | 7,041 | $170.00 footnote F1 | $1.20M | |
| ||||||
| James Bylund - Officer | Open-market sale | Common Stock | 2,191 | $151.21 footnote F1 | $331K | |
| ||||||
| Anthony Hunt | Open-market sale | Common Stock | 2,100 | $152.17 footnote F2 | $320K | |
| Anthony Hunt | Open-market sale | Common Stock | 2,923 | $153.14 footnote F3 | $448K | |
| Anthony Hunt | Open-market sale | Common Stock | 2,500 | $154.32 footnote F4 | $386K | |
| Anthony Hunt | Open-market sale | Common Stock | 3,000 | $155.45 footnote F5 | $466K | |
| Anthony Hunt | Open-market sale | Common Stock | 5,737 | $156.22 footnote F6 | $896K | |
| Anthony Hunt | Open-market sale | Common Stock | 1,956 | $157.11 footnote F7 | $307K | |
| Anthony Hunt | Option exercise | Stock Option (Right to Buy) | 2,952 | $0.00 | - | |
| Anthony Hunt | Option exercise | Common Stock | 2,952 | $33.87 | $100K | |
| Anthony Hunt | Open-market sale | Common Stock | 1,784 | $151.01 footnote F1 | $269K | |
| ||||||
| Anthony Hunt | Open-market sale | Common Stock | 3,741 | $154.92 footnote F2 | $580K | |
| Anthony Hunt | Open-market sale | Common Stock | 4,740 | $155.85 footnote F3 | $739K | |
| Anthony Hunt | Open-market sale | Common Stock | 4,959 | $156.65 footnote F4 | $777K | |
| Anthony Hunt | Open-market sale | Common Stock | 11,096 | $158.01 footnote F5 | $1.75M | |
| Anthony Hunt | Open-market sale | Common Stock | 464 | $158.51 footnote F6 | $74K | |
| Anthony Hunt | Option exercise | Stock Option (Right to Buy) | 25,000 | $0.00 | - | |
| Anthony Hunt | Option exercise | Common Stock | 25,000 | $33.87 | $847K | |
| ||||||
| Olivier Loeillot - Officer | Tax withholding / forfeiture | Common Stock | 1,248 footnote F1 | $145.23 | $181K | |
| ||||||
| Jason K. Garland - Officer | Tax withholding / forfeiture | Common Stock | 412 | $121.68 | $50K | |
| Anthony Hunt | Option exercise | Common Stock | 20,000 | $33.87 | $677K | |
| Anthony Hunt | Open-market sale | Common Stock | 96 | $116.34 | $11K | |
| Anthony Hunt | Open-market sale | Common Stock | 1,108 | $118.32 | $131K | |
| Anthony Hunt | Open-market sale | Common Stock | 3,262 | $119.64 | $390K | |
| Anthony Hunt | Open-market sale | Common Stock | 14,882 | $120.19 | $1.79M | |
| Anthony Hunt | Open-market sale | Common Stock | 7,584 | $121.42 | $921K | |
| Anthony Hunt | Open-market sale | Common Stock | 2,179 | $122.23 | $266K | |
| Anthony Hunt | Option exercise | Stock Option (Right to Buy) | 20,000 | $0.00 | - | |
| Olivier Loeillot - Officer | Tax withholding / forfeiture | Common Stock | 2,506 | $116.18 | $291K | |
| Violetta Hughes - Officer | Grant or award | Common Stock | 4,142 | $0.00 | - | |
| Violetta Hughes - Officer | Grant or award | Stock Option (Right to Buy) | 3,914 | $0.00 | - | |
 Martin D. Madaus | Open-market purchase | Common Stock | 1,800 | $112.13 | $202K | |
| Nicolas Barthelemy | Grant or award | Common Stock | 973 | $0.00 | - | |
| Nicolas Barthelemy | Grant or award | Stock Option (Right to Buy) | 1,800 | $0.00 | - | |
| Karen A. Dawes | Grant or award | Common Stock | 973 | $0.00 | - | |
| Karen A. Dawes | Grant or award | Stock Option (Right to Buy) | 1,800 | $0.00 | - | |
| Glenn P. Muir | Grant or award | Common Stock | 973 | $0.00 | - | |
| Glenn P. Muir | Grant or award | Stock Option (Right to Buy) | 1,800 | $0.00 | - | |
| Anthony Hunt | Option exercise | Common Stock | 11,808 | $33.87 | $400K | |
| Anthony Hunt | Option exercise | Stock Option (Right to Buy) | 11,808 | $0.00 | - | |
| Anthony Hunt | Option exercise | Common Stock | 24,246 | $33.87 | $821K | |
| Anthony Hunt | Open-market sale | Common Stock | 24,246 | $139.67 | $3.39M | |
| Anthony Hunt | Option exercise | Stock Option (Right to Buy) | 24,246 | $0.00 | - | |
| Olivier Loeillot - Officer | Tax withholding / forfeiture | Common Stock | 861 | $123.41 | $106K | |
| Jason K. Garland - Officer | Tax withholding / forfeiture | Common Stock | 367 | $123.41 | $45K | |
| Glenn P. Muir | Option exercise | Common Stock | 19,000 | $36.29 | $690K | |
| Glenn P. Muir | Option exercise | Stock Option (Right to Buy) | 19,000 | $0.00 | - | |
Item 3.02, 8.01, 9.01
Item 2.02, 9.01
Item 2.01, 7.01, 9.01
Item 5.02
Recent RGEN Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Olivier Loeillot | Officer, Director | 4,202 | $798K | View on EDGAR | |
| Olivier Loeillot | Officer, Director | 1,333 |
Stock trades in RGEN disclosed by members of the U.S. House in the last 12 months, newest first. Values are the ranges as filed.
| Member | Type | Traded | Disclosed | Value range | Owner | Days to disclose | Filing |
|---|---|---|---|---|---|---|---|
 Lisa C. McClainRepublican, MI-09 | Sale |
RGEN insider trading FAQ
What is the latest insider trade for RGEN?
REPLIGEN CORP (RGEN) had 9 insider filings in the last 90 days, with the most recent on 8 October 2026. The full record for RGEN runs to 56 Form 4 filings, the earliest from 20 November 2024. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying RGEN stock?
No insider purchases of RGEN were filed in the last 90 days. 1 purchase is on record for this company.
How many insiders are selling RGEN stock?
7 insider sales of RGEN were filed in the last 90 days, totaling $5.95M.
Where can I see RGEN SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects RGEN Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Brian Robb Douglass view on EDGAR
- - Olivier Loeillot view on EDGAR
- - Olivier Loeillot view on EDGAR
- - Jason K. Garland view on EDGAR
- - Olivier Loeillot view on EDGAR
- - Olivier Loeillot view on EDGAR
- - Olivier Loeillot view on EDGAR
- - Violetta Hughes view on EDGAR
- - Olivier Loeillot view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where RGEN's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow RGEN with a 7-day demo
- RGEN on your watchlist
- Every RGEN Form 4 filing on record
- Up to 3 months of RGEN price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
